Developing Antibodies Targeting LILRB2/TREM2 in Alzheimer’s Disease

Time: 3:15 pm
day: Day Two


• Discussing the molecular mechanisms of LILRB2-mediated inhibition of TREM2 signaling in microglia

• Developing LILRB2 antagonist antibodies as a novel therapeutic strategy for Alzheimer’s disease

• Engineering tetravalent TREM2 agonistic antibodies as potential therapies for Alzheimer’s disease